课件：肾癌靶向治疗省肿瘤大会吴晓安.ppt

IFN, interferon; Neph, nephrectomy; OS, overall survival. ? This was a combined analysis from 2 large phase?III trials that randomized more than 300?patients with metastatic renal cell carcinoma (RCC) to either nephrectomy or no nephrectomy followed by interferon?alfa for all patients. The median overall survival in patients who underwent upfront nephrectomy was nearly 6 months longer (P = .001). These data (which are from trials that accrued in the 1990s) resulted in debulking nephrectomy becoming a standard of care for patients who presented with metastatic kidney cancer. * * MSKCC, Memorial Sloan-Kettering Cancer Center; PFS, progression-free survival; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor. ? Everolimus is an oral inhibitor of the mammalian target of rapamycin (mTOR), which is similar to temsirolimus. In this large phase III study, RCC patients in whom sunitinib, sorafenib, or both had failed (possibly with other therapy) were randomized 2:1 to everolimus plus best supportive care or placebo plus best supportive care. * CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor. ? The main result for this trial was a survival advantage for patients randomized to everolimus: a median progression-free survival time of 4 months compared with 2 months for patients randomized to placebo. HR, hazard ratio; mRCC, metastatic renal cell carcinoma; MSKCC, Memorial Sloan-Kettering Cancer Center. ? This forest plot shows a subset analysis for various subsets in this particular trial. It shows no meaningful difference across subsets whether looking at MSKCC risk, type of previous treatment, age, sex, or geographic region. * IFN, interferon; Neph, nephrectomy; OS, overall survival. ? This was a combined analysis from 2 large phase?III trials that randomized more than 300?patients with metastatic renal cell carcinoma (RCC) to either nep